查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎(NASH)的全球市場:成長，未來預測，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180694

非酒精性脂肪性肝炎(NASH)的全球市場:成長，未來預測，競爭分析(2022年～2030年)

Non-Alcoholic Steatohepatitis Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

非酒精性脂肪性肝炎(NASH)，儘管治療的必要性高漲，沒有核可的治療藥。可是，治療藥中有有前途的開發平台，在II期的臨床試驗階段有20個以上的藥物候補。不久的將來，預計加入非酒精性脂肪性肝炎(NASH)市場的最有潛力的藥物，是III期實驗中的Elafibranor (Genfit)和Obeticholic Acid (Intercept) 。許多製藥大廠開發非酒精性脂肪性肝炎(NASH)用的醫藥品，預計將更加推動今後的非酒精性脂肪性肝炎(NASH)市場。

本報告提供全球非酒精性脂肪性肝炎(NASH)市場相關調查分析，競爭分析，市場促進因素和阻礙因素，各市場區隔、各地區的市場分析，企業簡介等資訊。

目錄

第1章 序文

  • 報告的說明
    • 報告的目的
    • 目標受眾
    • 主要的產品
  • 市場區隔
  • 調查手法
    • I期 - 2次調查
    • II期 - 1次調查
    • III期 - 專家的審查
    • 前提
    • 採用的方法

第2章 摘要整理

  • 市場概述:全球非酒精性脂肪性肝炎(NASH)市場
  • 全球非酒精性脂肪性肝炎(NASH)市場:各藥物(2021年)
  • 全球非酒精性脂肪性肝炎(NASH)市場:各地區(2021年)
  • 富有魅力的投資提案:各地區(2021年)

第3章 非酒精性脂肪性肝炎(NASH)市場:競爭分析

  • 主要的非酒精性脂肪性肝炎(NASH)市場供應商的市場定位
  • 非酒精性脂肪性肝炎(NASH)市場供應商採用的策略
  • 主要的產業策略
  • 階層分析(2021年/2030年)

第4章 非酒精性脂肪性肝炎(NASH)市場:常量分析和市場動態

  • 簡介
  • 全球非酒精性脂肪性肝炎市場金額(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • See-Saw分析

第5章 非酒精性脂肪性肝炎(NASH)市場:各藥物(2020年～2030年)

  • 市場概要
  • 成長與收益分析(2021年/2030年)
  • 市場區隔
    • Obeticholic Acid
    • Aramchol
    • Saroglitazar
    • Elafibranor

第6章 北美的非酒精性脂肪性肝炎(NASH)市場(2020年～2030年)

  • 市場概要
  • 各藥物
  • 各地區
    • 北美

第7章 英國、歐洲聯盟的非酒精性脂肪性肝炎(NASH)市場(2020年～2030年)

  • 市場概要
  • 各藥物
  • 各地區
    • 英國、歐洲聯盟

第8章 亞太地區的非酒精性脂肪性肝炎(NASH)市場(2020年～2030年)

  • 市場概要
  • 各藥物
  • 各地區
    • 亞太地區

第9章 南美的非酒精性脂肪性肝炎(NASH)市場(2020年～2030年)

  • 市場概要
  • 各藥物
  • 各地區
    • 南美

第10章 中東、非洲的非酒精性脂肪性肝炎(NASH)市場(2020年～2030年)

  • 市場概要
  • 各藥物
  • 各地區
    • 中東、非洲

第11章 企業簡介

  • AstraZeneca plc
  • Intercept Pharmaceutical Inc.
  • Galmed Pharmaceuticals
  • GENFIT SA
  • Allergan
  • Gilead Science Inc.
  • Zydus Cadila
  • Immuron Ltd.
  • Conatus Pharmaceuticals
  • Novo Nordisk
  • Enzo Biochem, Inc.
  • Raptor Pharmaceuticals
Product Code: 137585-08-22

Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases.

The report titled "Global Nonalcoholic Steatohepatitis Market- Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the Nonalcoholic Steatohepatitis market along with the market size and estimates for the duration 2022 to 2030. The research study covers in-depth analysis of market segments based on drug type, and different geographical region.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global Nonalcoholic Steatohepatitis market, attractive investment proposition and market positioning of key manufacturers sections.

Market size and forecast for these regional and country level markets are presented in this study for the period 2020-2030. Market growth rates for the forecast period 2022-2030 are also included in this report, considering 2021 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as pipeline analysis, market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global Nonalcoholic Steatohepatitis market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Nonalcoholic Steatohepatitis market. This report concludes with company profiles section that highlights major information about the key players engaged in global Nonalcoholic Steatohepatitis market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global Nonalcoholic Steatohepatitis market, offering market size and estimates for the period from 2022 to 2030, keeping in mind the above-mentioned factors.

Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. NASH affects around 2-5% of Americans and is considered to be one of the foremost causes of liver transplantation. Currently management of NASH includes lifestyle changes such as healthy diet, weight reduction and physical activity. Despite of growing treatment need there are no approved therapeutic for NASH. Some drugs are prescribed off-label such as Metformin which is used in type-2 diabetes and NASH. However, NASH therapeutics exhibit a lucrative pipeline with more than 20 drug candidates undergoing Phase II clinical trials. The most promising drug anticipated to enter the NASH market in the near future is Elafibranor (Genfit) and Obeticholic Acid (Intercept) which are undergoing phase III trials. Many pharma giants Allergan, Gilead Sciences, Novo Nordisk and Bristol-Myers Squibb are developing drugs for NASH which further boost the NASH market during the future period.

For the purpose of this study, the global non-alcoholic steatohepatitis market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. According to the British Liver Trust, Non-Alcoholic Fatty Liver Disease (NAFLD) is considered to be the most common liver problem in the Western world, affecting 20-30% of the population. North America held the largest share in the global non-alcoholic steatohepatitis market. In U.S. more than 25% of the population is affected by NAFLD as mentioned by the America Liver Foundation. Moreover, the rate of obesity is increasing rapidly in children and adult in the U.S. which is a primary risk factor for NASH. Furthermore, aggressive research and clinical trials in the region would further boost the non-alcoholic steatohepatitis market. Asia Pacific is one of the fastest growing NASH market due to alarming increase in the obesity rates in the region due to rising lifestyle changes. Moreover, the increasing number of research & development and supportive regulations are favouring the growth of non-alcohol steatohepatitis market.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Non-Alcoholic Steatohepatitis market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Non-Alcoholic Steatohepatitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

Obeticholic Acid

Aramchol

Saroglitazar

Elafibranor

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Non-Alcoholic Steatohepatitis market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Non-Alcoholic Steatohepatitis market?

Which is the largest regional market for Non-Alcoholic Steatohepatitis market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Non-Alcoholic Steatohepatitis market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Non-Alcoholic Steatohepatitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Non-Alcoholic Steatohepatitis Market
  • 2.2. Global Non-Alcoholic Steatohepatitis Market, By Drug, 2021 (US$ Million)
  • 2.3. Global Non-Alcoholic Steatohepatitis Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Non-Alcoholic Steatohepatitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Non-Alcoholic Steatohepatitis Market Vendors
  • 3.2. Strategies Adopted by Non-Alcoholic Steatohepatitis Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Non-Alcoholic Steatohepatitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Non-Alcoholic Steatohepatitis Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Obeticholic Acid
    • 5.3.2. Aramchol
    • 5.3.3. Saroglitazar
    • 5.3.4. Elafibranor

6. North America Non-Alcoholic Steatohepatitis Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
  • 6.3.Non-Alcoholic Steatohepatitis Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)

7. UK and European Union Non-Alcoholic Steatohepatitis Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
  • 7.3.Non-Alcoholic Steatohepatitis Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)

8. Asia Pacific Non-Alcoholic Steatohepatitis Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
  • 8.3.Non-Alcoholic Steatohepatitis Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)

9. Latin America Non-Alcoholic Steatohepatitis Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
  • 9.3.Non-Alcoholic Steatohepatitis Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)

10. Middle East and Africa Non-Alcoholic Steatohepatitis Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
  • 10.3.Non-Alcoholic Steatohepatitis Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. AstraZeneca plc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Intercept Pharmaceutical Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Galmed Pharmaceuticals
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. GENFIT SA
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Allergan
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Gilead Science Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Zydus Cadila
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Immuron Ltd.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Conatus Pharmaceuticals
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Novo Nordisk
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Enzo Biochem, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Raptor Pharmaceuticals
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 2 North America Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 3 U.S. Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 4 Canada Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 7 UK Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 8 Germany Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 9 Spain Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 10 Italy Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 11 France Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 13 Asia Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 14 China Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 15 Japan Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 16 India Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 17 Australia Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 18 South Korea Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 19 Latin America Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 20 Brazil Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 21 Mexico Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 24 GCC Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 25 Africa Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Non-Alcoholic Steatohepatitis Market By Drug, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Non-Alcoholic Steatohepatitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Non-Alcoholic Steatohepatitis Market: Quality Assurance
  • FIG. 5 Global Non-Alcoholic Steatohepatitis Market, By Drug, 2021
  • FIG. 6 Global Non-Alcoholic Steatohepatitis Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Non-Alcoholic Steatohepatitis Market, 2021
  • FIG. 8 Market Positioning of Key Non-Alcoholic Steatohepatitis Market Players, 2021
  • FIG. 9 Global Non-Alcoholic Steatohepatitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Non-Alcoholic Steatohepatitis Market, By Drug, 2021 Vs 2030, %
  • FIG. 11 U.S. Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 18 France Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 20 China Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 22 India Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Non-Alcoholic Steatohepatitis Market (US$ Million), 2020 - 2030